Janice L Gabrilove, MD
img_Janice L Gabrilove
PROFESSOR | Oncological Sciences
PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
Cancer (Oncology)
Research Topics
Bioinformatics, Biophysics, Computational Biology, Computer Simulation, Drug Design and Discovery, Integrins, Mathematical and Computational Biology, Membrane Proteins/Channels, Protein Complexes, Protein Structure/Function, Signal Transduction, Theoretical Biology, Theoretical Biophysics
Role of Hematopoietic Factors in Normal Hematopoietic Cell Reconstitution
Dr. Gabrilove is a pioneer in the development of our understanding of the biology of hematopoietic growth factors and their clinical utility in promoting hematopoietic reconstitution. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy induced myelosuppression and severe chronic neutropenia. Her initial studies also demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation has revolutionized the way in which we perform marrow transplantation today, which is conducted almost exclusively utilizing G-CSF mobilized PBPC. This laboratory is currently investigating:

  • the development of novel therapeutic strategies in CLL; and
  • the role of arsenicals as experimental therapeutics to induce apoptosis.
  • MD, Icahn School of Medicine at Mount Sinai

    Residency, Internal Medicine, New York Presbyterian Hospital/Columbia University

    Fellowship, Hematology & Oncology, Memorial Sloan-Kettering Cancer Center


    Medical Oncology
    American Board of Internal Medicine


    Best Doctors

    New York Magazine

    Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

    Below are financial relationships with industry reported by Dr. Gabrilove during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

    Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

    • Association for Clinical and Translational Science

    Royalty Payments:

    • Cephalon, Inc.
    • Amgen Inc.

    Scientific Advisory Board:

    • Leukemia & Lymphoma Society

    Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.